They have more irons in the fire than ever before. There's the pending merger with LyGenesis, that will instantly turn them into a phase 2a company. It's also possible that Morphoceuticals, Inc. will join them, somewhere down the road. AgeX's most exciting technology, that's been transferred to their subsidiary Reverse Bioengineering, is likely to become autonomous, which was probably the plan, all along. One reason is that its success could undermine much of the other projects.
The AgeX staff has recently granted themselves a significant number of call options, with a term of 10 years. Juvenescence has three main shareholders, who presently own 51% of the company. AgeX in turn belongs to Juvenescence, by currently over 50%. AgeX's pre-merger shareholders are supposed to retain an 80% "economic interest" in Reverse Bio, which is likely their most exciting project. On behalf of the three main investors, co-founder Jim Mellon just recently affirmed that none of them will be selling any shares. From the way it sounded, he probably meant, they won't be selling in years, maybe not even in decades. They intend to see the mission through.
Unfortunately, as much as they might be one of the most exciting bets of all time, they're also not exactly known for being communicative, for a number of reasons. You might almost say, they operate in some sort of indefinite stealth mode, with a number of issues to work out. But the veil will lifted, eventually. As much as this might not be very popular with the troops, this company, if successful, could be one of the best examples of the stock market, being about reallocating money, from the impatient to the patient. Your call.
